MOUNJARO

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
  The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
  biopharma_dive · 2d ago
• STAT+: Lilly bypasses Australian pharmacies with DTC model
  Eli Lilly is launching LillyDirect to deliver Mounjaro straight to Australian patients’ doors — and local doctors and pharmacists aren’t thrilled.
  stat · 2d ago
• Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
  Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic…
  biospace · 2d ago
• 3 takeaways from a European obesity scientific meeting
  Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…
  biopharma_dive · 3d ago
• Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
  Patients had adverse events after receiving a Fresenius Kabi medicine that experienced manufacturing deviations.
  biospace · 3d ago
• STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
  A final Medicare rule aimed at lowering prices for doctor-administered drugs applies to only four companies and saves 96% less than the initial proposal
  stat · 3d ago
• Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trial
  Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
  raps · 4d ago
• Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
  EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and ty…
  biospace · 4d ago
• #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
  MILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data revealed Wednesday show that Lilly's amylin-incretin combination del…
  endpoints · 4d ago
• STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
  An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
  stat · 4d ago